Sucroferric oxyhydroxide monotherapy for hyperphosphatemia in Indian chronic kidney disease patients undergoing hemodialysis: A phase IV, single-arm, open-label study

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

291

Figures (1-2)

Tables (1-5)

Sum=429

Publishing Process of This Article

Item

Count

Browse

Download

Sum=94

Jun 25, 2025 (publication date) through Apr 30, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Nephrol. Jun 25, 2025; 14(2): 100117
Published online Jun 25, 2025. doi: 10.5527/wjn.v14.i2.100117

Table 3 Percentage of patients have < 5.5 mg/dL serum phosphorus (n = 94), n (%)

Citation: Niranjan MR, Srinivasa S, Gupta V, Bhalla AK, Gaikwad A, Wangikar P, Suryawanshi S, Gajbe P. Sucroferric oxyhydroxide monotherapy for hyperphosphatemia in Indian chronic kidney disease patients undergoing hemodialysis: A phase IV, single-arm, open-label study. World J Nephrol 2025; 14(2): 100117
URL: https://www.wjgnet.com/2220-6124/full/v14/i2/100117.htm
DOI: https://dx.doi.org/10.5527/wjn.v14.i2.100117